Toremifene is well tolerated in men at high risk of developing prostate cancer

被引：0
|
作者：
Steiner, M [1 ]
Boger, R [1 ]
Barnette, G [1 ]
Mitchell, J [1 ]
Price, D [1 ]
机构：
[1] GTx006 211 Study Grp, Memphis, TN USA
来源：
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2004年 / 13卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1940S / 1940S
页数：1
相关论文
共 50 条
  • [1] Evaluation of toremifene in reducing prostate cancer incidence in high risk men.
    Steiner, MS
    Boger, R
    Barnette, G
    Mitchell, J
    Bostwick, D
    Price, D
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (11) : 1886S - 1887S
  • [2] Toremifene could prevent prostate cancer in high-risk patients
    Nature Clinical Practice Urology, 2006, 3 (11): : 572 - 573
  • [3] Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
    Smith, Matthew R.
    Morton, Ronald A.
    Barnette, K. Gary
    Sieber, Paul R.
    Malkowicz, S. Bruce
    Rodriguez, Domingo
    Hancock, Michael L.
    Steiner, Mitchell S.
    JOURNAL OF UROLOGY, 2010, 184 (04): : 1316 - 1321
  • [4] Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
    Smith, Matthew R.
    Morton, Ronald A.
    Barnette, K. Gary
    Sieber, Paul R.
    Malkowicz, S. Bruce
    Rodriguez, Domingo
    Hancock, Michael L.
    Steiner, Mitchell S.
    JOURNAL OF UROLOGY, 2013, 189 (01): : S45 - S50
  • [5] Re: Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
    Langley, Ruth E.
    Cafferty, Fay H.
    Pollock, Philip A.
    Price, Patricia
    Abel, Paul D.
    JOURNAL OF UROLOGY, 2011, 185 (06): : 2430 - 2431
  • [6] The lifetime risk of developing prostate cancer in white and black men
    Merrill, RM
    Weed, DL
    Feuer, EJ
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1997, 6 (10) : 763 - 768
  • [7] Re: Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Reply
    不详
    JOURNAL OF UROLOGY, 2011, 185 (06): : 2431 - 2432
  • [8] SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer
    Rucinska, Monika
    Kieszkowska-Grudny, Anna
    Nawrocki, Sergiusz
    STRAHLENTHERAPIE UND ONKOLOGIE, 2016, 192 (07) : 449 - 457
  • [9] Black men in the UK have an elevated risk of developing prostate cancer
    Nature Clinical Practice Urology, 2008, 5 (12): : 640 - 640
  • [10] `Norplant' well tolerated in developing countries
    Reactions Weekly, 2001, 856 (1) : 6 - 6
12345